PF-06882961

Overview

PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity	2025/04/04	NCT06910839	Phase 1	Terminated	Pfizer
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity	2024/08/23	NCT06568731	Phase 1	Completed	Pfizer
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese	2024/08/22	NCT06567327	Phase 1	Completed	Pfizer
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.	2024/08/07	NCT06541678	Phase 1	Completed	Pfizer
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults	2023/12/01	NCT06153758	Phase 1	Completed	Pfizer
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS	2021/10/26	NCT05093205	Phase 1	Completed	Pfizer
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus	2021/05/17	NCT04889157	Phase 1	Completed	Pfizer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy	2021/04/09	NCT04839393	Phase 1	Completed	Pfizer
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity	2021/01/13	NCT04707313	Phase 2	Completed	Pfizer
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity	2020/11/09	NCT04621227	Phase 1	Completed	Pfizer

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Pfizer Pursues $7.3 Billion Acquisition of Metsera to Enter Rapidly Expanding Anti-Obesity Drug Market

a month ago

Pfizer is acquiring Metsera, a nine-month-old biotech company, for $7.3 billion to gain access to innovative obesity therapeutics including a once-monthly GLP-1 agonist.

Trump Administration's Drug Pricing Order Targets GLP-1 Market, Threatening Novo Nordisk and Eli Lilly Dominance

6 months ago

The Trump administration's 2025 Executive Order on drug pricing specifically targets high-margin weight-loss drugs like Ozempic and Wegovy, with "Most-Favored-Nation" pricing mandates potentially forcing U.S. prices down by 59%.

Eli Lilly's Oral GLP-1 Orforglipron Shows Promising Phase 3 Results for Weight Management

6 months ago

Eli Lilly's oral GLP-1 receptor agonist orforglipron demonstrated significant efficacy in Phase 3 clinical trials, potentially expanding the company's dominance in the rapidly growing GLP-1 market.

Biolexis Therapeutics Confirms Novel Allosteric Mechanism for Oral GLP-1 Receptor Agonist

8 months ago

Biolexis Therapeutics has successfully resolved the cryoEM structure of BLX-7006, confirming a first-in-class allosteric activation mechanism for the GLP-1 receptor that differs from all existing approaches.

JPM25: Pfizer Focuses on Obesity, Regeneron Anticipates Key Data, BioNTech Expands Cancer Pipeline

10 months ago

• Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action. • Regeneron anticipates Phase III data readouts for itepekimab in COPD and fianlimab in melanoma, potentially expanding its portfolio alongside Dupixent. • BioNTech is advancing its mRNA-based cancer immunotherapies, including BNT327/PM8002 for solid tumors and BNT323/DB-1303, an ADC for endometrial cancer. • Sarepta Therapeutics reported strong initial sales for Elevidys in Duchenne muscular dystrophy and is pursuing a Phase III trial for limb-girdle muscular dystrophy.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access